Pharmaceutical companies businesses

Unfortunately, the tension between the computational chemists and the medicinal chemists at pharmaceutical companies did not ease in the 1970s. Medicinal chemists were at the top of the pecking order in corporate research laboratories. This was an industry-wide problem revealed in conversations at scientific meetings where computational chemists from industry (there were not many) could informally exchange their experiences and challenges. (Readers should not get the impression that the tension between theoreticians and experimentalists existed solely in the business world. It also existed in academic chemistry departments.)... 

Nevertheless, the Clintons healthcare reform scheme had a deleterious effect on the hiring of new computational chemists. The job market for computational chemists in the United States fell from a then record high in 1990 to a depression in 1992-1994 [119]. This happened because pharmaceutical companies were afraid to expand until they were sure that the business climate was once again hospitable for growth. The healthcare reform proposal was defeated in the United States Congress, but it took a year or two before pharmaceutical companies started rebuilding their workforces. 

On Treacherous Ground, 50 of the world s biggest pharmaceutical companies are challenged to perform in the most difficult environment ever, Med. Ad News, September 1, 2002. Haspeslagh, P, Portfolio planning Uses and limits. Harvard Business Review, January-February, 1982, p. 58. 

Today, pharmaceutical companies are linking CDS to business systems such as SAP, chemical structure databases, electronic laboratory notebooks, and corporate data warehousing solutions. Many commonly used software products utilize COM Automation (Microsoft s Component Object Model) to provide a powerful array of programmable objects that allow seamless connections between applications. 

Internationally-operating pharmaceutical companies as well as CROs are busy these days with similar activities in order to gain first-hand experience with the new format, and to take part in the voluntary phase by fQing applications simultaneously as soon as possible. 

Most (if not all) companies within the pharmaceutical industry have recognised that such requirements are now a permanent part of doing business, and are developing internal health economics expertise, both on a global (corporate) and on a country-specific level. It should be noted that because of the multidisciplinary nature of this area of research, pharmaceutical company-based health economists cannot operate in isolation from the other disciplines within the company. It is therefore vital that pharmaceutical physicians understand the basic principles of health economic evaluations in order to work with the health economists in the development of high-quality analyses. 

The promotional formula and the capping of allowable promotional expenses operate in favour of the pharmaceutical companies with large existing sales to the NHS, and to the disadvantage of small companies or companies wishing to start up business in the United Kingdom. 

Some of these government agencies and private companies, because of the nature of their business, will utilize the services of an analytical chemistry laboratory as part of their overall need to assure the required quality operation. For example, municipal governments will employ the use of an analytical chemistry laboratory to test their water supply on a regular basis to make sure it is free of toxic chemicals. The pharmaceutical company will house an analytical chemistry laboratory within its facility to routinely test the products it produces and the raw materials that go into these products to make certain that they meet the required specifications. A fertilizer plant will utilize an analytical chemistry laboratory to confirm that the composition of its product meets the specifications indicated on the individual bags of fertilizer. Companies that produce a food product, such as snack chips, cheese, cereal, or meat products, will have an analytical chemistry laboratory as part of their operation because they want to have the assurance that the... 

Animal health is a segment of the life sciences industry at the interface of pharmaceuticals and agrochemicals. Global sales were 15 billion in 2005 ( 14.5 billion in 2004, 13.8 billion in 2001, inflation-adjusted). Of the top 10 companies, 9 are business units or spinoffs from pharmaceutical companies (see Table 11.9). The industry is rather concentrated, with the top 10 companies accounting for 75% of total sales. As they do in pharma, US companies dominate in animal health products. Many of the veterinary products in the portfolios had originally been developed for human use or as pesticides. In the pet (respectively companion animal) segment, which comprises cats, dogs, birds, some rodents, reptiles, and horses and represents about 40% of the total market, the association with human health is particularly prominent. 

---